INmune Bio Inc expected to post a loss of 50 cents a share - Earnings Preview

Inmune Bio

29/10/2024 21:06

* INmune Bio Inc  INMB.OQ   INMB.O  is expected to show a
fall in
quarterly revenue when it reports  results on October 31 for the
period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for INmune Bio Inc is for a
loss
of 50 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for INmune Bio
Inc is
$20.50​, above​ its last closing price of $6.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.63       -0.63      -0.50     Beat    20.6
 Mar. 31 2024  -0.53       -0.53      -0.61     Missed  -14
 Jan. 1 0001               -0.44      -0.47     Missed  -6.8​
 Sep. 30 2023  -0.39       -0.39      -0.48     Missed  -21.5
 ​​Jun.        -0.39       -0.40      -0.36     Beat    9.2
 30 2023                                                
 Mar. 31 2023  -0.02       -0.02      -0.36     Missed  -1,700
                                                        ​
 Dec. 31 2022  -0.47       -0.48      -0.32     Beat    34
 Sep. 30 2022  -0.53       -0.52      -0.43     Beat    18.1
 This summary was machine generated October 29 at 21:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)